MedTrace Logo

Evaluating Treatment Efficacy in Oral Lichen Planus: The Role of Salivary Biomarkers

NCT06332365 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-03-27

No results posted yet for this study

Summary

Lichen planus, a chronic autoimmune mucocutaneous disorder, affects 0.5% to 2.2% of diverse populations. The treatment for oral lichen planus (OLP) includes a range of options, both topical and systemic therapies. Recent research has highlighted the potential of hyaluronic acid as a drug alternative, potentially offering effective management for OLP and alleviating the discomfort of this chronic condition. The objective was to assess the impact of topical hyaluronic acid on salivary oxidative stress markers in individuals suffering from oral lichen planus

Conditions

  • Oral Lichen Planus
  • Oral Lichen Planus Related Stress

Interventions

COMBINATION_PRODUCT

Acetonide triamcinolone 0.2% +hyaluronicacid 1%

topical application cream form twice a day for 4 weeks

DRUG

Corticoid Acetonide triamcinolone 0.2%

topical application cream form twice a day for 4 weeks

DRUG

Hyaluronic acid 1%

topical application cream form twice a day for 4 weeks

Sponsors & Collaborators

  • Pia Lopez Jornet

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-03
Primary Completion
2023-12-15
Completion
2024-02-19

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06332365 on ClinicalTrials.gov